Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Arovella Therapeutics Limited (ALA) Price & Analysis

ALA Stock Chart & Stats

A$0.05A$0.00(3.92%)
At close: 4:00 PM EDT
AUD 0.05AUD 0.055AUD 0.06AUD 0.0653 Aug17 Aug31 Aug14 Sep28 Sep12 Oct26 Oct
Day’s Range
AUD 0.05 - AUD 0.06
52-Week Range
AUD 0.05 - AUD 0.10
Previous Close
AUD 0.05
Volume
855.69K
Average Volume (3M)
836.12K
Market Cap
AUD 64.07M
Enterprise Value
AUD 60.24M
Total Cash (Recent Filing)
AUD 14.35M
Total Debt (Recent Filing)
AUD 0
Price to Earnings (P/E)
―
Beta
1.50
Next Earnings
N/A
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Cell-therapy Platform Focus

Arovella has a defined strategic focus on adoptive cell therapies and engineered immune-cell technologies for cancer. Concentrating research around CAR and related platform components can support a coherent development roadmap and create opportunities to advance multiple treatments from shared scientific capabilities.

Minimal Leverage

Minimal debt and positive equity reduce near-term solvency pressure compared with a highly leveraged biotechnology company. This balance-sheet profile preserves greater flexibility to direct available resources toward research and development, while limiting interest and refinancing burdens during continued clinical development.

Improving Free Cash Flow Trend

The improvement in free cash flow versus 2025 is a constructive directional signal within an otherwise cash-burning profile. If sustained, better cash conversion could gradually reduce the pace at which Arovella consumes funding, although the company still needs to manage a substantial ongoing financing requirement.

Bears Say

No Scalable Commercial Revenue

Arovella has not yet established a scalable commercial revenue base, leaving its financial performance dependent on future development progress rather than recurring product sales. Zero annual revenue limits internal funding capacity and makes the company more exposed to delays in advancing its pipeline toward commercialization.

Persistent Operating Losses

Recurring and substantial operating losses show that the current business model is not yet economically self-sustaining. Without evidence of improving margins, continued research and development spending is likely to remain ahead of revenue generation, making future profitability dependent on successful pipeline advancement and eventual commercialization.

Ongoing Cash Funding Dependence

Sustained negative operating cash flow means Arovella cannot currently fund its activities from operations and remains reliant on external financing. Continued cash consumption can constrain strategic flexibility and may require additional capital, while the balance-sheet summary also identifies dilution or capital-consumption risk.

Arovella Therapeutics Limited News

ALA FAQ

What was Arovella Therapeutics Limited’s price range in the past 12 months?
Arovella Therapeutics Limited lowest share price was AU$0.05 and its highest was AU$0.10 in the past 12 months.
What is Arovella Therapeutics Limited’s market cap?
Arovella Therapeutics Limited’s market cap is AU$64.07M.
When is Arovella Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Arovella Therapeutics Limited’s earnings last quarter?
Arovella Therapeutics Limited released its earnings results on Sep 02, 2026. The company reported -AU$0.004 earnings per share for the quarter.
Is Arovella Therapeutics Limited overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Arovella Therapeutics Limited pay dividends?
Arovella Therapeutics Limited does not currently pay dividends.
What is Arovella Therapeutics Limited’s EPS estimate?
Arovella Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Arovella Therapeutics Limited have?
Arovella Therapeutics Limited has 1,208,851,800 shares outstanding.
What happened to Arovella Therapeutics Limited’s price movement after its last earnings report?
Arovella Therapeutics Limited reported an EPS of -AU$0.004 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Arovella Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:ALA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology